An interventional study of Hydroxyethylstarch 6% 130/0.4 and standard volume therapy in Kidney Function Tests, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-12-03.
Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Treatment
Recent studies have shown an increased incidence of renal replacement therapy after the use of Hydroxyethylstarchs (HES) in patients admitted in the intensive care unit. However, studies showing detrimental effects of HES have been conducted in mostly non-surgical subjects. There are very few studies analyzing the effects of HES on renal function after cardiac surgery, a population already at risk of renal dysfunction.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain is the lead sponsor of 342 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
These patients have received Hydroxyethylstarch 6% 130/0.4 intraoperatively or postoperatively in addition to standard volume therapy.
Drug: Hydroxyethylstarch 6% 130/0.4 · Other: standard volume therapy
These patients have not received Hydroxyethylstarch 6% 130/0.4 at any time point. Only standard volume therapy has been used.
Other: standard volume therapy
Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
Also known as: Any volume therapy has been recorded
Renal dysfunction based on RIFLE (Risk; Injury; Failure; Loss; End-stage) criteria.
Time frame: Up to 45 days
Mortality
Time frame: Up to 45 days
No study locations are listed for this record.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain